REPL—Bottomed Out & Breaking Structure | High-Risk Catalyst PlayReplimune Group, Inc.BATS:REPLibraheeemzREPL has been in a prolonged downtrend, but appears to have finally put in a long-term bottom near its all-time low of $1.50. Price has since broken and successfully retested a major trendline resistance — a structurally bullish sign that suggests the worst may be behind it. The bias is now bullish as long as price holds above $8.50 on a daily closing basis. 🎯 Target: $17 🛑 Invalidation: Daily close below $8.50 Fundamental Catalyst: REPL is a clinical-stage biotech developing oncolytic immunotherapies. Its lead drug RP1 targets advanced melanoma patients who have failed PD-1 therapy — a high unmet need space. The FDA recently issued a second CRL, which is a setback, but the market is clearly pricing in a path forward. Importantly, the company has cash runway extended into Q1 2027, reducing dilution risk near term. This is a high-risk / high-reward catalyst play — any positive FDA development could be a major upside trigger.